Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk.

about

Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk.

Item

http://www.wikidata.org/entity/Q49993491

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Clinical interpretation of pat ...... sts: navigating moderate risk.

@en

Clinical interpretation of pat ...... sts: navigating moderate risk.

@nl

type

Item

label

Clinical interpretation of pat ...... sts: navigating moderate risk.

@en

Clinical interpretation of pat ...... sts: navigating moderate risk.

@nl

prefLabel

Clinical interpretation of pat ...... sts: navigating moderate risk.

@en

Clinical interpretation of pat ...... sts: navigating moderate risk.

@nl

P1476

Clinical interpretation of pat ...... sts: navigating moderate risk.

@en

P2093

Allison H West

http://www.w3.org/2001/XMLSchema#string

Caroline M Weipert

http://www.w3.org/2001/XMLSchema#string

Jessica Stoll

http://www.w3.org/2001/XMLSchema#string

Kathleen R Blazer

http://www.w3.org/2001/XMLSchema#string

Matthew Jones

http://www.w3.org/2001/XMLSchema#string

Sarah M Nielsen

http://www.w3.org/2001/XMLSchema#string

Sonia S Kupfer

http://www.w3.org/2001/XMLSchema#string

P2860

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

ClinVar: public archive of interpretations of clinically relevant variants

Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study.

Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine

Contralateral Prophylactic Mastectomy (CPM) Consensus Statement from the American Society of Breast Surgeons: Data on CPM Outcomes and Risks.

Counselling framework for moderate-penetrance cancer-susceptibility mutations.

Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls.

Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment.

Cancer risks and mortality in heterozygous ATM mutation carriers.

P2888

s10689-018-0070-x

P31

scholarly article

P356

10.1007/S10689-018-0070-X

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey N Weitzel

Olufunmilayo Olopade

P577

2018-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101039517

http://www.w3.org/2001/XMLSchema#string

P698

29445900

http://www.w3.org/2001/XMLSchema#string

P932

6092249

http://www.w3.org/2001/XMLSchema#string